Invion Limited has progressed its Photosoft clinical programs with new patient dosing and an expanded collaboration with Hanlim Pharm, backed by a successful $2 million share placement to accelerate development.
Invion Limited has marked significant progress in its cancer treatment pipeline, dosing the first patient in a pivotal skin cancer trial and reporting encouraging prostate cancer results, while securing fresh funding to support ongoing development.
